Other
Jun 2025Co-founder Richard Barrett publicly said Guardian Bio was being put into hibernation; Ananya Zutshi posted the same day confirming hibernation and that both founders were moving on to new opportunities.
SourceDendritic cell-based platform for cancer therapy
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Guardian Bio is a Boston-based biotechnology startup founded in 2022 that developed a patient-derived cDC1 dendritic-cell therapy platform (Guard-cDC1) for late-stage solid tumors, combining regenerative medicine with immunotherapy. Public evidence suggests the company later entered hibernation in June 2025 after a small preclinical program backed by Y Combinator and other early-stage support.
Primary product
Guard-cDC1, a patient-derived cDC1 dendritic-cell therapy platform for late-stage solid tumors
Founded
2022
Headquarters
Boston, Massachusetts, United States
Team size
1-10
Industry
Biotechnology
Sub-industry
Immunotherapy / cell therapy
Business model
Open Positions
0 jobs at Guardian Bio
No open positions
Check back later for new openings